Incyte (INCY) Other Accumulated Expenses (2017 - 2022)
Incyte's (INCY) quarterly Other Accumulated Expenses came in at $209.5 million in Q2 2022, up 64.68% YoY from $127.2 million in Q2 2021, and up 21.83% on a QoQ basis from $172.0 million in Q1 2022.
Analysis
Incyte (INCY) Other Accumulated Expenses (2017 - 2022) Analysis & Trends
Incyte (INCY) has 6 years of Other Accumulated Expenses data on file, last reported at $209.5 million in Q2 2022.
- Quarterly Other Accumulated Expenses rose 64.68% year-over-year to $209.5 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $209.5 million (up 64.68% YoY) and the FY2021 annual result came in at $168.4 million, up 58.86% from the prior year.
- Other Accumulated Expenses climbed to $209.5 million in Q2 2022, from $172.0 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $209.5 million in Q2 2022 to a low of $34.6 million in Q4 2018.
- A 5-year average of $105.3 million and a median of $99.1 million in 2020 frame the typical range for Other Accumulated Expenses.
- Annual changes were most pronounced in 2019 — Other Accumulated Expenses soared 111.82% — and 2020, when it jumped 44.78%.
- Tracing INCY's Other Accumulated Expenses over 5 years: stood at $34.6 million in 2018, then soared by 111.82% to $73.2 million in 2019, then jumped by 44.78% to $106.0 million in 2020, then surged by 58.86% to $168.4 million in 2021, then grew by 24.4% to $209.5 million in 2022.
- The last three Other Accumulated Expenses figures came in at $209.5 million (Q2 2022), $172.0 million (Q1 2022), and $168.4 million (Q4 2021), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 209.50 Mn |
| Mar 31, 2022 | 171.96 Mn |
| Dec 31, 2021 | 168.41 Mn |
| Sep 30, 2021 | 142.45 Mn |
| Jun 30, 2021 | 127.22 Mn |
| Mar 31, 2021 | 110.10 Mn |
| Dec 31, 2020 | 106.01 Mn |
| Sep 30, 2020 | 92.15 Mn |
| Jun 30, 2020 | 77.80 Mn |
| Mar 31, 2020 | 73.05 Mn |
| Dec 31, 2019 | 73.22 Mn |
| Jun 30, 2019 | 47.40 Mn |
| Mar 31, 2019 | 39.91 Mn |
| Dec 31, 2018 | 34.57 Mn |
| Dec 31, 2017 | 22.81 Mn |